Login
Toggle navigation
Videos
Categories
Trending
Flash is missing. Download it from
Adobe
.
VIDEO / RINCONADA: El convenio con la empresa Lipigas permitirá mejorar el acceso al gas en la zona.
00:10:00
Watch Full Video
×
Please Login to watch Full video
Login
+ ADD TO Wishlist
×
Please login
Login
Share On Facebook
Share On Twitter
Angel Solimano is the CEO of Empresas Lipigas.
Recent Videos
00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences
Suggestions
00:10:00
Navigating Sub Trusts: Insights from Elizabeth Talbot - Estate Plan Coordinator at Talbot Law Group, P.C.
00:10:00
Expensive Equities: Insights from Columbia Threadneedle Investments
00:10:00
New development partnership aims to revolutionize breast cancer diagnosis|Andrew Newland, CEO, Angle PLC.
00:10:00
Insights from Brad Boat of Capital Group's American Funds|Bradley J. Vogt,manager,capital Group
00:10:00
Alstom CEO Discusses Bombardier Acquisition on "Good Morning Business | Henri Poupart Lafarge - CEO of Alstom
00:10:00
Jindalee Expands Portfolio with 80% Stake in Deep Well Nickel-Copper-PGE Project
00:10:00
Supply Chain Resilience: Investment Opportunities in a Changing Landscape | Bill Maldonado, CEO , Eastspring Investments.
00:10:00
NCR Chairman & CEO Bill Nuti discusses career opportunities and shares his comments.|Michael D. Hayford Retiring as NCR Chief Executive Officer
00:10:00
Abhishek Bansal on the Positive Impact of Extended Derivatives Market Timings | Abhishek Bansal , CEO , Abans Holdings Ltd.
00:10:00
Essential traits of curiosity and coachability|Shaun Arora, Managing Director at MiLA Capital
00:10:00
New Brunswick's Third Session: Legislative Highlights | Mike Holland - Minister of Natural Resources and Energy Development
00:10:00
RNC Minerals: Key Developments and Market Sentiments at the One-to-One Conference in London